LINCOLN, Neb., April 27 /PRNewswire-FirstCall/ -- In remarks at the annual shareholders meeting, Pfizer Chairman and Chief Executive Officer Hank McKinnell told shareholders that the company has “more than turned the corner” in research and development, with more than 150 new medicines in development and more than 80 other projects underway. He noted that with four new products launched in 2005 and six more planned in 2006, “2005 and 2006 will be the two best launch years in Pfizer’s history.”
He added: “Pfizer is succeeding in finding, developing and bringing forward the innovations that bring hope to patients, jobs for communities and value for investors. We are building the Pfizer for the next generation -- a company whose future lies in a new wave of medicines now beginning to reach patients. We serve shareholders best by serving patients first, and our aim is to return Pfizer to its hallmark strong growth in shareholder value over the long-term.”
In other business, all 13 of the company’s directors stood for and were re-elected to one-year terms. In other voting, shareholders approved both the selection of KPMG as Pfizer’s independent auditor for 2006 and management proposal to amend Pfizer’s charter to eliminate the supermajority vote requirements and fair price provision. No shareholder resolutions receive a majority vote.
Photo: A free corporate logo to accompany this story is availableimmediately via Wieck Photo Database to any media with telephoto receiveror electronic darkroom, PC or Macintosh, that can accept overheadtransmissions. To retrieve a logo, please call 972-392-0888.//Company News On-Call: http://www.prnewswire.com/comp/688250.htmlPfizer Inc
CONTACT: Paul Fitzhenry, of Pfizer Inc, +1-212-733-4637
Web site: http://www.pfizer.com/
